



Brain-Targeted Drug Delivery

Guest Editor:

Dr. Flávia Sousa
Istituto Italiano di Tecnologia,
16163 Genova, Italy

Deadline for manuscript
submissions:
closed (10 August 2022)

Message from the Guest Editor

Dear Colleagues,

At present, brain diseases affect 1 in 6 people worldwide, and include a wide range of neurological diseases from Alzheimer's and Parkinson's disease to epilepsy, brain injuries, brain cancer, neuroinfections and strokes. The treatment of these diseases is complex and limited due to the presence of the blood–brain barrier (BBB), which covers the entirety of the brain. The BBB not only has the function of protecting the brain from harmful substances, but is also a metabolic barrier and a transport regulator of nutrients/serum factors/neurotoxins. Knowing these characteristics when it comes the treatment of brain diseases makes it easy to understand the lack of efficacy of therapeutic drugs, resulting from the innate resistance of the BBB to permeation. To overcome this limitation, drug delivery systems based on nanotechnology/microtechnology have been wisely developed. Brain-targeted drug delivery allows targeted therapy with a higher therapeutic efficacy and low side effects because it targets moieties present in the drug delivery systems

Dr. Flávia Sousa
Guest Editor





an Open Access Journal by MDPI

Editor-in-Chief

Prof. Dr. Patrick J. Sinko

Department of Pharmaceutics,
Ernest Mario School of
Pharmacy, Rutgers University,
Piscataway, NJ 08854, USA

Message from the Editor-in-Chief

Pharmaceutics (ISSN 1999-4923) is an online open access journal on the science and technology of pharmaceutics and biopharmaceutics. The scientific community, the wider community and the general public have unlimited and free access to the content as soon as a paper is published; this open access to your research ensures your findings are shared with the widest possible audience. Please consider publishing your impressive work in this high quality journal. We would be pleased to welcome you as one of our authors.

Author Benefits

Open Access: free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility: indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank: JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q1 (Pharmaceutical Science)

Contact Us

Pharmaceutics Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland

Tel: +41 61 683 77 34
www.mdpi.com

mdpi.com/journal/pharmaceutics
pharmaceutics@mdpi.com
X@MDPIpharma